Humana (HUM) stock
NYSE
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $54B
- As of Nov 13, 2026
- P/E
- 43.34x
- Trailing twelve months
- P/B
- 2.87x
- Latest reported equity
- P/S
- 0.35x
- Trailing twelve months
- ROE
- 6.6%
- Trailing twelve months
- Dividend yield
- 0.79%
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $54B
- As of Nov 13, 2026
- P/E
- 43.34x
- Trailing twelve months
- P/B
- 2.87x
- Latest reported equity
- P/S
- 0.35x
- Trailing twelve months
- ROE
- 6.6%
- Trailing twelve months
- Dividend yield
- 0.79%
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
43.34x
P/B
2.87x
P/S
0.35x
Earnings and dividend metrics▾
Earnings
EPS
$10.38
Earnings per share
BPS
$156.88
Book value per share
ROE
6.6%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $10.38 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $156.88 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 6.6%.
Dividends
Yield
0.79%
Dividend per share
$3.54
Payout ratio
34.5%
Consecutive years
15+ yrs
Yield uses fiscal 2025 dividends · Dividend per share and payout ratio are for fiscal 2025.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $354.00 before tax.
- Payout ratio — 34.5% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 15 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 26.1% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $32.6B+26.1%
$29.4B
Jul–Sep '24
$32.6B
Jul–Sep '25
$41.2B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 6, 2026.
- Earnings per share decreased 17.9% from the same quarter a year earlier.
- Revenue increased 26.1% from the same quarter a year earlier.
- Operating income decreased 81.2% from the same quarter a year earlier.
- Net income decreased 16.9% from the same quarter a year earlier.
Filed Nov 6, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Frederick Wayne A.I.Director · Nov 10, 2026Open-market sale440 shares · $194KAvg. price $440.5750 shares held after
- Dintenfass DavidPresident, Enterprise Growth · Nov 10, 2026Gift230 shares · $0Avg. price $025,177 shares held after
- Ventura Joseph CChief Legal Officer · Nov 9, 2026Open-market sale5,495 shares · $2.4MAvg. price $433.851421,910 shares held after
- Ventura Joseph CChief Legal Officer · Nov 9, 2026Gift437 shares · $0Avg. price $021,473 shares held after
- Nundy ShantanuChief Medical Officer · Sep 1, 2026Grant or award2,549 shares · $0Avg. price $02,549 shares held after
- Smith Paul JohnDirector · Aug 1, 2026Grant or award544 shares · $0Avg. price $0544 shares held after
- Crawford Frederick JohnDirector · Aug 1, 2026Grant or award544 shares · $0Avg. price $0544 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary8-KHumana said it entered into a new joint venture agreement with funds and accounts managed by HPS Investment Partners, a BlackRock unit. The new joint venture replaces the existing joint ventures with WCAS-affiliated funds and CenterWell, and BlackRock will acquire WCAS's current equity stake.Published Oct 13, 2026 · Filed Oct 13, 2026Read the summary →
- AI summary8-KHumana said that based on final 2027 Medicare Advantage Star Ratings data (Bonus Year 2028) provided by CMS on October 8, 2026, it exceeded its goal of Top Quartile results, which is defined as Stars revenue PMPM 10% above the peer group median.Published Oct 9, 2026 · Filed Oct 9, 2026Read the summary →
- AI summary8-KHumana said on July 28, 2026 the Board of Directors expanded the number of authorized directors from eleven to thirteen and elected Frederick J. Crawford and Paul J. Smith as directors, effective on the same day.Published Sep 30, 2026 · Filed Jul 29, 2026Read the summary →
- Humana said it entered into a new joint venture agreement with funds and accounts managed by HPS Investment Partners, a BlackRock unit. The new joint venture replaces the existing joint ventures with WCAS-affiliated funds and CenterWell, and BlackRock will acquire WCAS's current equity stake.Read the full analysis →
- Humana said that based on final 2027 Medicare Advantage Star Ratings data (Bonus Year 2028) provided by CMS on October 8, 2026, it exceeded its goal of Top Quartile results, which is defined as Stars revenue PMPM 10% above the peer group median.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Humana (HUM) stock information
NYSE
Humana (HUM) is listed on NYSE. Its market capitalization is about $54B. On trailing-twelve-month earnings the P/E ratio is 43.34, and the P/B ratio is 2.87. Return on equity is 6.6%. These figures are computed in-house from official filings and are reference information only.
Humana — frequently asked questions
- What is the P/E ratio of Humana (HUM)?
- On a trailing-twelve-month basis, HUM trades at a P/E ratio of 43.34. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Humana?
- HUM has a market capitalization of about $54B. The figure moves with the share price and is refreshed each trading day.
- Does Humana pay a dividend?
- HUM has a dividend yield of about 0.79%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.